IO biotech
VerifiedClinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
($30m) (Public information from Jul 2024)
Share price
$1.29 IOBT
Company register number 36474483
Copenhagen Capital Region of Denmark (HQ)
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (8125802 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (8653 %) | - |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | $0.0 | round |
| investor investor investor | $0.0 | round | |
| investor investor | $0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor | $0.0 | round | |
| N/A | $0.0 Valuation: $0.0 -32.0x EV/LTM EBITDA | round | |
* | $75.0m | Private Placement VC | |
| Total Funding | 000k | ||
Related Content
Recent News about IO biotech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.